Bcl-2 antigen expression in luminal A and triple-negative breast cancer

Escórcio-Dourado, Carla Solange; Martins, Luana Mota; Simplício-Revoredo, Camila Maria; Sampaio, Fabiane Araújo; Tavares, Cléciton Braga; Silva‐Sampaio, João Paulo da; Borges, Umbelina Soares; Alves-Ribeiro, Francisco Adelton; Lopes-Costa, Pedro Vitor; Lima-Dourado, José Charles; Silva, Benedito Borges da

doi:10.1007/s12032-017-1022-2

Cited by 13 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bcl-2 is recognized as an important factor with anti-apoptotic effects and was originally identified in human follicular B cell lymphoma (36). Bcl-2 expression has been revealed to be downregulated in triple-negative breast cancer (37,38).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑615‑5p regulates the proliferation and apoptosis of breast cancer cells by targeting HSF1

Liu

2021

Exp Ther Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

MicroRNA‑615‑5p regulates the proliferation and apoptosis of breast cancer cells by targeting HSF1

Liu

2021

Exp Ther Med

View full text Add to dashboard Cite

“…A consistent and strong positive correlation between Bcl-2 positivity and hormone receptor expression is reported in breast cancer, and concerns both ER and PR [7, 9, 12, 19, 49, 51, 52, 54, 55, 58–60]. Bcl-2 positivity of breast cancers has been associated with a lower Ki-67 proliferation index [7, 12, 16, 50, 60], with the luminal phenotype [7], and especially the luminal-A phenotype [64]. Indeed, BCL2 is upregulated by estrogens in breast cancer cells [65], explaining why Bcl2-positive expression in breast cancer may be considered a sign of ER functional activity [7].…”

Section: Discussionmentioning

confidence: 99%

Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study

et al. 2019

View full text Add to dashboard Cite

BackgroundCats spontaneously develop invasive mammary carcinomas with high clinical aggressiveness, and are considered relevant animal models for human breast cancer. Bcl-2 is an anti-apoptotic pro-survival protein, whose expression is associated with a favorable outcome in human breast cancer. The aim of our study was to determine the frequency of Bcl-2 expression in feline invasive mammary carcinomas (FMCs), its relationship with other clinicopathologic variables, and its prognostic value. This retrospective study included 180 FMCs, diagnosed in female cats treated by surgery only, with a 2-year follow-up post-mastectomy. Bcl-2, ER, PR, Ki-67, HER2, and CK5/6 expression were determined by automated immunohistochemistry. A receiver-operating-characteristic curve was used to set the threshold for Bcl-2 positivity.ResultsThe cohort comprises 32% (57/180) luminal FMCs defined by ER and/or PR positivity, and 68% (123/180) triple-negative FMCs (negative for ER, PR, and HER2). Bcl-2 expression was considered as positive when at least 65% of tumor cells were immunohistochemically stained. Thirty-one out of 180 FMCs (17%) were Bcl-2-positive. There was no significant association between Bcl-2 expression, and the tumor size, nodal stage, histological grade, or ER, PR, Ki-67, HER2, and CK5/6 expression. By multivariate survival analysis (Cox proportional-hazards regression), Bcl-2 positivity in FMCs was associated with longer disease-free interval (p = 0.005, HR = 0.38), overall survival (p = 0.028, HR = 0.61), and cancer-specific survival (p = 0.019, HR = 0.54) independently of other powerful prognostic factors such as pathologic tumor size, pathologic nodal stage, and distant metastasis. The positive prognostic value of Bcl-2 was confirmed in both luminal FMCs, of which 9/57 (16%) were Bcl-2-positive, and in basal-like triple-negative (ER–, PR–, HER2–, CK5/6+) FMCs, of which 14/76 (18%) were Bcl-2-positive.ConclusionsCompared to human breast cancer, Bcl-2 positivity in feline invasive mammary carcinomas is also associated with better outcome, but is less common, and not associated with ER, PR, and HER2 expression. Cats with spontaneous Bcl-2-positive FMCs could be useful in preclinical trials evaluating anti-Bcl-2 strategies for chemoresistant luminal or triple-negative breast cancers.

show abstract

“…Osada et al suggested a relationship between CV risk assessed with SCORE chart and predicting molecular response to TKIs [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study

Varga

Ţilea

Petra

et al. 2020

JCM

View full text Add to dashboard Cite

Introduction. Cardiovascular risk factors, pre-existing comorbidities, molecular factors, and the direct effects of second- and third-generation BCR-ABL1 tyrosine kinase inhibitors on the vascular endothelium contribute to the progression of cardiovascular (CV) events, especially atherothrombotic conditions. The study objective was to evaluate comorbidities, the cardiovascular risk profile, and events throughout the chronic myeloid leukaemia disease course. Methods. Retrospective data from adults who experienced haematology treatment at a single centre were continuously updated and followed throughout the disease course. A total of 43 subjects conforming with the inclusion and exclusion criteria of the study protocol were finally recruited. The median disease course was 77.0 ± 17.5 months. Statistical analyses were performed. Results. More than three CV risk factors were identified in 41.9% of cases. Almost half of the cases had relevant comorbidities (Charlson Comorbidity Index (CCI) ≥ 4), and no statistically significant comorbidities were found when comparing the tyrosine kinase inhibitor (TKI) treatment subgroups (p = 0.53). The patients at high and very high CV risk, according to Systematic Coronary Risk Evaluation (SCORE) risk classification, had 75.0% CV events (12/22 patients), p = 0.45. Throughout the disease course, 19 cardiovascular events were reported in 37.2% patients (13 males/3 females, p < 0.03). Conclusion. To the best of our knowledge, this is the first study exploring cardiovascular risk factors in Romanian chronic myeloid leukaemia patients. This study reinforces the need for close long-term follow-up that should be performed by a multidisciplinary team. The target should be not only the disease and specific drug-related toxicities but, also, the identification of cardiovascular and metabolic risk factors before the commencement of and throughout TKI therapy.

show abstract

Bcl-2 antigen expression in luminal A and triple-negative breast cancer

Cited by 13 publications

References 29 publications

MicroRNA‑615‑5p regulates the proliferation and apoptosis of breast cancer cells by targeting HSF1

MicroRNA‑615‑5p regulates the proliferation and apoptosis of breast cancer cells by targeting HSF1

Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study

Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study

Contact Info

Product

Resources

About